65,437 trials
Acne Vulgaris
Primary: Absolute Change From Baseline in Facial Total Lesion Counts to Week 12 — -69.1; -48.1 Lesion counts
Perimenopausal Disorder · Depression
Primary: Change in Frontostriatal Reactivity to Reward During MID fMRI Task — .0704; .0475; .0623; .0280 percent signal change — p=0.53
Rotator Cuff Tear · Postoperative Pain
Primary: Postoperative Visual Analog Scale Scores — 30; 20 score/units on a scale
Myopia
Primary: Subjective Response for Vision Satisfaction — 24; 28; 30; 24 Participants
Dementia · Alzheimer's Disease · Frontotemporal Dementia
Primary: Zarit Burden Interview-Short Form — 24.58; 25.59 score on a scale
Down Syndrome · Mild Cognitive Impairment
Primary: Tolerability of Nicotine Intervention — 1; 3 Participants
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Adverse Event Rate — 1 Participants
Lung Carcinoma · Solitary Pulmonary Nodule · Cigarette Smoking Behavior
Primary: Ability of 18F-FSPG PET/CT to Discriminate Benign From Malignant Nodules — 0.706; 0.778; 0.731; 0.817 proportion, range 0 to 1, higher better
Head and Neck Cancer
Primary: Percentage of Participants With Local Regional Control — 91.1 percentage of subjects
Acne
Primary: Number of Participants With C. Acnes Bacterium Culture After Treatment — 20; 20; 16 Participants
Metabolic Syndrome X · Overweight · Hypertension
Primary: Insulin Sensitivity — .56; 0.55; 0.66; 0.70 % suppression inf rate 56 pmol/m2/min
Diabetic Ketoacidosis · Type 1 Diabetes Mellitus
Primary: Rate of Rebound Hyperglycemia — 20; 18 Participants
Coronary Artery Disease · Coronary Stenosis · Angina, Unstable
Primary: Number of Participants With Residual Ischemia (iFR <0.90) — 112 participants
Metastatic Non-small Cell Lung Cancer · Locally Advanced Urothelial Cancer · Metastatic Urothelial Cancer
Primary: Overall Response Rate (ORR) — 40.0; 34.8; 37.9; 23.5 percentage of participants
HIV/AIDS · Antiviral Toxicity · Antiviral Drug Adverse Reaction
Primary: Change in Mitochondrial Function [Cellular Oxygen Consumption (COC)] Over 12 Months After Switch of Antiretrovirals. — 50; 70 pmoles O2/min — p=<0.001